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Abstract In Milan hypertensive rats (MHS) the sequence of
events going from renal function to cell membrane ion transport
abnormalities and finally to the molecular defect responsible of
hypertension has been established. A polymorphism of the
cytoskeletal protein adducin has been identified as a likely
culprit for hypertension in these rats. Two point mutations in
MHS K- (F316Y) and L- (Q529R) adducin genes have been
shown to be associated with hypertension in genetic crosses of
MHS and MNS rats.
Also in humans, a polymorphism of K-adducin gene (Gly460Trp)
has been found to be significantly associated both to hypertension
and salt sensitivity.
Studies aimed at clarifying the functional role of K-adducin
variants have shown that adducin from the MHS rats is able to
stimulate Na-KATPase activity both after transfection in renal
tubular cells and after incubation with the enzyme in a cell-free
system. Also the human hypertensive K-adducin variant displays
the same activity of MHS adducin in a cell-free system.
Therefore, both in humans and in rats, adducin polymorphisms
may affect blood pressure and kidney function by modulating the
overall capacity of tubular epithelial cells to transport ions,
through variations of the Na-KATPase activity.
However adducin polymorphisms account for only a portion of
hypertension both in humans and rats. Therefore additive or
epistatic interactions with other genes involved in renal sodium
handling need to be studied.
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1. Introduction
Hypertension is a signi¢cant risk factor for heart attack and
stroke, and represents a major public health burden because
of its high prevalence (e.g. 15^20% of the European and
American populations). Although blood pressure is known
to have a strong genetic determination, the genes responsible
for susceptibility to essential hypertension are mostly un-
known. From studies in human and animal models it is clear
that several genetic loci are involved in regulation of blood
pressure and hypertension [1]. The Milan hypertensive rats
(MHS) and its control normotensive strain (MNS) have
been validated as an appropriate model for at least a sub-
group of patients with primary hypertension [2]. In these ani-
mals, the complex trait hypertension has been dissected from
the primary organ abnormality to the molecular abnormality
(candidate gene) through the following steps: (1) Kidney
transplantation experiments provided the major and more
consistent evidences that the kidney plays a causal role in
the pathogenesis of rat genetic hypertension [3,4]. The pressor
role of the kidney has also been demonstrated in humans [5,6].
(2) Na transport is faster [7,8] and cell volume is lower both in
erythrocytes [9] and in renal tubular MHS cells than in the
corresponding MNS cells [10]. (3) Erythrocyte functional dif-
ferences are genetically determined within the stem cells and
are genetically associated to hypertension in F2 hybrids [11].
(4) The di¡erence in cell membrane ion transport disappears
after removal of the membrane skeleton, suggesting the in-
volvement of some of its components [12]. (5) Cross immuni-
zation between MHS and MNS with cytoskeletal extracts of
the other strain were then performed and yielded to the pro-
duction of antibodies against a protein subsequently identi¢ed
as adducin [13].
The scope of this review is to brie£y summarise: (1) The
biochemical function of adducin; (2) the association of K-ad-
ducin to hypertension; (3) the relation between K-adducin
polymorphisms and renal sodium handling in essential hyper-
tension.
2. Biochemical functions of adducin
Adducin is a heterodimeric protein that consists of K, L and
Q similar subunits. Adducin subunits have structurally distinct
domains: an NH2 terminal globular head (40 kDa), an 8 kDa
neck domain and a COOH terminal domain, which is respon-
sible for the association of actin and spectrin complexes and
contains sites of phosphorylation [14,15].
Adducin promotes the binding of spectrin with actin and
also directly binds actin and bundles actin ¢laments. It is
present in many tissues and within regions of cell-cell contacts
[16]. Its role is believed to be the regulation of the assembly of
spectrin and actin [17]. As a consequence adducin can modu-
late the lattice structure of the cytoskeleton and the exposure
of transmembrane proteins. Adducin can move from the cy-
toplasm to cell to cell contact sites under the control of intra-
cellular Ca2 and phosphorylation.
One of the functions of actin-spectrin-based membrane
skeleton is to organize certain integral membrane proteins
and to couple them to cytoplasmic proteins [18]. Spectrin
molecules are linked in a polygonal array, the vertices of
which are formed by short actin ¢laments [19]. At these junc-
tions, accessory proteins are found including adducin. In the
cell, the interaction between cytoskeletal protein network and
integral membrane proteins is fundamental for several func-
tions such as maintenance of cell polarity [20,21] and regula-
tion of ion transports [22,23]. It has been demonstrated that
the actin-based cytoskeleton interacts with the band 3-anion
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exchanger [24], the epithelial Na channels [22], the Na-K-Cl
cotransport [25] and the Na-KATPase [26,27].
MHS and MNS rats di¡er at the molecular level for two
missense mutations in K (F316Y) and L (Q529R) subunits
of adducin [28]. These polymorphisms are associated with
blood pressure variation in the Milan rats [25], and they
account for up to 50% of the total blood pressure di¡erence
between the two strains. Transfection experiments in rat
kidney epithelial cells (NRK-52E) with MHS and MNS rat
adducin cDNA have clearly demonstrated the functional role
of adducin polymorphisms [29]. Cells transfected with MHS
adducin show: (1) a signi¢cant increase in Na-K pump activ-
ity at Vmax and of Na-K pump units compared with cells
carrying the MNS adducin [29]. (2) Studies in a cell-free sys-
tem of the interaction between actin and normal or mutated
adducin [29] have shown that mutated adducin leads to a
higher ¢nal level of ¢lamentous actin. Moreover actin bun-
dling is favored by MHS adducin. Therefore the mutated
protein interferes with a cellular fundamental biological func-
tion, that is the ability of actin monomers to polymerize into
¢laments.
Recently a series of evidences have further supported the
concept of a functional interaction between adducin and the
Na-K pump: (1) When compared to their MNS controls,
MHS rats show an increased enzymatic activity of the outer
medulla Na-KATPase. This increase precedes and follows the
development of hypertension and it is associated to a higher
number of functionally active pump sites on the cell mem-
brane surface and to higher cellular levels of the complemen-
tary mRNA and protein [30]. Therefore, in vivo, renal Na-
KATPase is up-regulated in MHS at all ages. (2) Experiments
in a cell-free system have demonstrated that adducin puri¢ed
from rat erythrocytes stimulates Na-KATPase activity [31].
This e¡ect seems to be speci¢c since it occurs at nanomolar
concentrations, it is retained by a restricted portion of the
COOH-terminal tail of 200 amino acids and is lost when
the tail fragment is reduced to 31 amino acids or when native
adducin is extensively proteolyzed. Moreover this modulation
is related to the genetic variants of both K (F316Y) and L
(Q529R) adducins, with a higher a⁄nity for MHS adducin
compared to the MNS one [31]. (3) Adducin and Na-KATP-
ase co-precipitate both in a cell-free system [31] and in a cell
system [32], using monoclonal antibodies either to adducin or
to Na-KATPase. (4) Na-KATPase and adducin are co-local-
FEBS 20223 29-6-98
Fig. 1. A schematic model of adducin interaction with cytoskeleton and membrane protein in renal tubular cell. The cytoskeleton protein addu-
cin is shown associated with actin ¢laments and a subunit of the Na-KATPase. The barbed ends of actin ¢laments are associated to spectrin
¢laments and other constituents of membrane skeleton as talin, fodrin and integrin. The Na-K pump is responsible of the Na gradient across
the basolateral membrane which, in turn, allows the entrance of Na across the luminal membrane. Adducin polymorphisms may a¡ect Na
transport by modulating the Na-K pump.
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ized exclusively at the basolateral side of renal tubules [31]
(Fig. 1).
Preliminary experiments have shown that also human K-
adducin polymorphism is able to di¡erently modulate the ac-
tivity of rat puri¢ed Na-KATPase [31].
3. K-Adducin polymorphisms in human essential hypertension
The Milan hypertensive strain has been validated as an
appropriate model for at least a subgroup of patients with
primary hypertension. For this reason and since adducin
gene has a very high homology (about 94%) in rat and man
we tested if K-adducin polymorphism could also a¡ect blood
pressure level in humans. Three di¡erent studies were per-
formed: (1) Four highly polymorphic markers, mapping at
di¡erent distances from the K-adducin locus (4p16.3), were
studied in a case-control study on the assumption that possi-
ble functional mutations could be in linkage disequilibrium
with the markers mapping in close proximity to the K-adducin
locus [33] ; (2) linkage of these markers to hypertension in
a¡ected sib-pairs [34] ; (3) variants of human K-adducin gene
were identi¢ed and studied in normotensive and hypertensive
populations [34].
The study with four polymorphic multiallelic markers
showed that the marker mapping closest to the K-adducin
locus (20 kb) was highly signi¢cantly associated to hyperten-
sion. The association with the other markers decreased with
increasing distance from the K-adducin locus. Similarly, in the
second study [34], a signi¢cant linkage was detected for all
markers in a¡ected sib-pairs, and the percentage of shared
alleles decreased with increasing distance of the markers
from the K-adducin locus. The third study demonstrated a
linkage disequilibrium between a new K-adducin polymor-
phism (Gly460Trp) and hypertension in two Caucasian pop-
ulations. The Gly460Trp polymorphism was tested in a case-
control study in an Italian and in a French population. A
signi¢cant association of the mutated allele (Trp) with hyper-
tension was shown (20.7% in hypertensives vs. 13.6% in nor-
motensives; P = 0.001). Recently the Gly460Trp variant has
been found associated to hypertension also in a Japanese
case-control study [35]. The frequency of the 460Trp allele is
much higher in this study than that reported in our study on
European populations (65.6% in Japanese hypertensives vs.
52.9% in Japanese normotensives, P = 0.0087). Moreover, in
a sample of Italian general population the relationship of this
polymorphism with blood pressure and cardiovascular struc-
ture has been investigated [36]. A trend towards higher blood
pressure values was observed in patients carrying the 460Trp
allele. These studies demonstrate a signi¢cant linkage of the
K-adducin locus to hypertension in di¡erent population stud-
ies.
4. K-Adducin polymorphism and renal sodium handling
As discussed above, K-adducin polymorphism a¡ects the
activity of the Na-KATPase. These data provide the genetic
molecular basis for a type of primary hypertension caused by
a faster renal tubular Na reabsorption, in view of the key role
of this enzyme in transtubular Na transport. Based on this
hypothesis, we investigated the e¡ect of K-adducin polymor-
phism on blood pressure response to acute salt sensitivity test,
according to Weinberger’s protocol [37], in hypertensive pa-
tients. Blood pressure variation after sodium loading and de-
pletion was greater in heterozygotes Gly460Trp than in wild-
type homozygotes. 88% of the heterozygotes were salt sensi-
tive compared to 41% of the homozygotes. In spite of similar
sodium intake the heterozygotes had signi¢cantly lower basal
plasma renin activity [34]. In another group of hypertensive
patients we tested the blood pressure response to chronic diu-
retic treatment [34]. Blood pressure decrease was about double
in heterozygotes than in wild-type homozygotes. The relative
risk of being salt sensitive or responder to the chronic diuretic
treatment was respectively 9 and 4.8 for patients bearing the
460Trp allele. We also evaluated the pressure-natriuresis rela-
tionship during acute variation of body sodium [38]. The
slopes obtained were signi¢cantly di¡erent according to the
genotype (Gly/Trp 0.029 þ 0.004 vs. Gly/Gly 0.007 þ 0.002
mm Hg/mmol/min, P = 0.0001). Fig. 2 shows the change in
mean blood pressure (MAP) going from volume depletion
to volume load in 28 Gly/Trp and 80 Gly/Gly patients. For
the same degree of variation in body sodium, the magnitude
of blood pressure changes is greater in Gly/Trp than in Gly/
Gly patients clearly demonstrating that the former have a
regulation of blood pressure that is very sensitive to variations
in total body sodium. Moreover, patients bearing the 460Trp
allele had signi¢cantly lower plasma renin activity. Also in the
Japanese study [35] the 460Trp allele is signi¢cantly associated
to a lower plasma renin activity. These ¢ndings suggest that in
humans adducin is associated to hypertension, seems to mod-
ulate sodium reabsorption and could be involved in a low
renin hypertension with normal potassium and aldosterone,
indistinguishable from ‘essential’ hypertension.
Since essential hypertension is a complex genetic trait, we
tested if this peculiar modulation of renal sodium handling
shown by the Gly460Trp patients could be determined also
by the synergistic e¡ect between K-adducin and some other
gene involved in sodium homeostasis. Preliminary data show
that K-adducin and angiotensin converting enzymes have a
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Fig. 2. Changes in mean arterial pressure (MAP) and changes in
body sodium from baseline during sodium depletion or load in 28
Gly/Trp (closed circle) and 80 Gly/Gly (open circle) hypertensive pa-
tients. The changes in MAP were calculated from the baseline of
each test. Body sodium was calculated either by subtracting the so-
dium excretion from the sodium load or simply by subtracting the
amount of sodium excretion after furosemide. For the same degree
of variation in body sodium, the magnitude of blood pressure
changes is greater in Gly/Trp than in Gly/Gly patients (P = 0.0001)
(from [38] with some modi¢cations).
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synergistic e¡ect in causing blood pressure changes following
acute modi¢cations of Na balance [39].
5. Conclusions
The ¢ndings discussed in this review demonstrate that: (1)
Adducin mutations and blood pressure levels are associated
both in rats and humans. (2) The a⁄nity for the Na-K pump
of the ‘hypertensive’ adducin variant is greater than that of
the ‘normotensive’ one in both species. (3) A pathophysiolog-
ical link exists between the adducin variants and the events
leading to hypertension. To our knowledge the adducin poly-
morphism is the ¢rst genetic mechanism shown to be relevant
in blood pressure regulation of both rats and humans.
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